ILDong: Ildong wins Chinese and Japanese patent for GLP-1 new drug candidate

Ildong Pharmaceutical has received material patents in China and Japan for its metabolic disease drug candidate, ID110521156, which is being developed through its subsidiary Yunovia.ID110521156 is the GLP-1 receptor agonist (glucagon-like peptide-1 receptor agonist) family of drugs and acts as an an